The development of avastin

Tumor Angiogenesis: Basic Mechanisms and Cancer Therapy

Volumn , Issue , 2008, Pages 611-653

  Mass, Robert ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 68649122485     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-33177-3_35     Document Type: Chapter

References (43)

1. Algire GH, Chalkley HW, Legallais FY, Park HD (1945) Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 6:73-85
2. Blum JL, Jones SE, Buzdar AU et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 127:485-493
3. Carter P et al (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. PNAS 89:4285-4289
4. De Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:2938-2947
5. Ehrmann RL, Knoth M (1968) Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy. J Natl Cancer Inst 41:1329-1341
6. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4-25
7. Ferrara N, Winer J, Burton T, Rowland A, Siegel M, Phillips HS et al (1993) Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. J Clin Invest 91:160-170
8. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
9. Folkman J, Merler E, Abernathy C, Williams G (1971) Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133:275-288 (abstract/free full text)
10. Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (in press)
11. Green MC, Buzdar AU, Smith T et al (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983-5992
12. Greenblatt M, Shubik P (1968) Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. J Natl Cancer Inst 41:111-124
13. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colon cancer. N Engl J Med 350:2335-2342
14. Ide AG, Baker NH, Warren SL (1939) Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am J Roentgenol 42:891-899
15. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, De Vore RF, Gaudreault J, Damico LA, Holmgren E, Kabbinacar F (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic nonsmall-cell lung cancer. J Clin Oncol 22:2184-2191
16. Jones PT et al (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522-525
17. Kabbinavar F et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65
18. Kabbinavar FF, Schulz J, McCleod M et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in firstline metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23:3697-3705
19. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423-36
20. Kim K, La B, Houck K., Winer J, Ferrara N (1992) The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7:53-64
21. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362:841-844
22. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309
23. Mass RD et al (2004) Clinical benefit from bevacizumab (BV) in responding (R) and non-responding (NR) patients (pts) with metastatic colorectal cancer (mCRC). Proc Am Soc Clin Oncol 23 (abstr 3514)
24. Meta-analysis Group in Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus adminstration in advanced colorectal cancer. J Clin Oncol 16:301-308
25. Miller K D, Chap LI, Holmes FA et al (2005) Randomi zed phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799
26. Miller KD, Wang M, Gralow J et al (2007) A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). J Clin Oncol (submitted for publication)
27. Miller RA, Oseroff AR, Stratte PT, Levy R (1983) Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62:988-995
28. Neuberger MS et al (1985) A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature 314:268-270
29. Petrelli N, Douglas O et al (1989) Modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7:1419-1426
30. Picus J (2003) The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): Initial results of CALGB 90006. Proc Am Soc Clin Oncol 22 (abstr 1578)
31. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599
32. Radinsky R, Ellis LM (1996) Molecular determinants in the biology of liver metastasis. Surg Oncol Clin North Am 5:215-229
33. Reese D (1999) A phase II trial of humanized monoclonal anti-vascular endothelial growth factor antibody (rhuMAb VEGF) in hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 18 (abstr 1355)
34. Riechmann L et al (1988) Reshaping human antibodies for therapy. Nature 332:323-327
35. Rothenberg ML, Oza AM, Bigelow RH et al (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21:2059-2069
36. Saltz LB, Cox JV, Blancke C et al (2000) Irinotecan plus fluorourical and leucovorin for metastatic colorectal cancer. N Eng J Med 343:905-914
37. Sandler A. Gray R. Perry MC. Brahmer J. Schiller JH. Dowlati A. Lilenbaum R. Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New Engl J Med 355:2542-2550
38. Schiller J, Harrington D, Belani C et al (2002) Comparison of four chemotherapy regimens for advanced non-small cell lung cancer: ECOG 1594. N Engl J Med 346:92-98
39. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55:3964-3968
40. Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR et al (1997) Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 132:541-546
41. Tokunaga T, Oshika Y, Abe Y, Ozeki Y, Sadahiro S, Kijima H et al (1998) Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 77:998-1002
42. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N (1995) Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95:1789-1797
43. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434